ChitogenX Inc. (CHGX.CN)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.84 Million CAD | -29.62% |
| 2022 | 5.45 Million CAD | 1.09% |
| 2021 | 5.39 Million CAD | 141.37% |
| 2020 | 2.23 Million CAD | -5.37% |
| 2019 | 2.36 Million CAD | 273.88% |
| 2018 | 632.01 Thousand CAD | -5.59% |
| 2017 | 669.46 Thousand CAD | -23.27% |
| 2016 | 872.48 Thousand CAD | 314.77% |
| 2015 | -406.24 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 4.11 Million CAD | 3.0% |
| 2024 Q1 | 3.99 Million CAD | 4.06% |
| 2023 Q1 | 6.56 Million CAD | 20.33% |
| 2023 FY | 3.84 Million CAD | -29.62% |
| 2023 Q2 | 3.61 Million CAD | -44.89% |
| 2023 Q4 | 3.84 Million CAD | 13.14% |
| 2023 Q3 | 3.39 Million CAD | -6.19% |
| 2022 Q2 | 4.98 Million CAD | 42.85% |
| 2022 Q4 | 5.45 Million CAD | -9.22% |
| 2022 FY | 5.45 Million CAD | 1.09% |
| 2022 Q1 | 3.49 Million CAD | -35.32% |
| 2022 Q3 | 6.01 Million CAD | 20.51% |
| 2021 Q1 | 3.11 Million CAD | 39.18% |
| 2021 FY | 5.39 Million CAD | 141.37% |
| 2021 Q4 | 5.39 Million CAD | 21.66% |
| 2021 Q3 | 4.43 Million CAD | 21.1% |
| 2021 Q2 | 3.66 Million CAD | 17.71% |
| 2020 Q3 | 2.47 Million CAD | -24.47% |
| 2020 Q1 | 3.09 Million CAD | 30.89% |
| 2020 Q2 | 3.27 Million CAD | 5.85% |
| 2020 Q4 | 2.23 Million CAD | -9.58% |
| 2020 FY | 2.23 Million CAD | -5.37% |
| 2019 Q1 | 1.08 Million CAD | 70.88% |
| 2019 Q3 | 2.01 Million CAD | 39.46% |
| 2019 Q4 | 2.36 Million CAD | 17.5% |
| 2019 Q2 | 1.44 Million CAD | 33.52% |
| 2019 FY | 2.36 Million CAD | 273.88% |
| 2018 Q3 | 458.72 Thousand CAD | 24056.29% |
| 2018 Q1 | 1.08 Million CAD | 62.56% |
| 2018 FY | 632.01 Thousand CAD | -5.59% |
| 2018 Q4 | 632.01 Thousand CAD | 37.78% |
| 2018 Q2 | 1899.00 CAD | -99.83% |
| 2017 Q2 | 366.97 Thousand CAD | 89.72% |
| 2017 Q1 | 193.42 Thousand CAD | -77.83% |
| 2017 FY | 669.46 Thousand CAD | -23.27% |
| 2017 Q4 | 669.46 Thousand CAD | 1173.4% |
| 2017 Q3 | 52.57 Thousand CAD | -85.67% |
| 2016 Q4 | 872.48 Thousand CAD | 64.43% |
| 2016 Q3 | 530.62 Thousand CAD | 4.43% |
| 2016 Q1 | 258 Thousand CAD | 163.51% |
| 2016 FY | 872.48 Thousand CAD | 314.77% |
| 2016 Q2 | 508.1 Thousand CAD | 96.93% |
| 2015 Q4 | -406.24 Thousand CAD | 0.0% |
| 2015 FY | -406.24 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -125.08 Thousand CAD | 3169.912% |
| Asep Medical Holdings Inc | -44.72 Thousand CAD | 8686.57% |
| BetterLife Pharma Inc. | 207.85 Thousand CAD | -1747.486% |
| BioVaxys Technology Corp. | -977.00 CAD | 393139.918% |
| Rapid Dose Therapeutics Corp. | 2.29 Million CAD | -67.494% |
| Defence Therapeutics Inc. | 1.68 Million CAD | -127.232% |
| Entheon Biomedical Corp. | -344.63 Thousand CAD | 1214.229% |
| Gemina Laboratories Ltd. | 284.33 Thousand CAD | -1250.515% |
| Glow Lifetech Corp. | 116.15 Thousand CAD | -3206.07% |
| Lexston Life Sciences Corp. | -390.4 Thousand CAD | 1083.594% |
| Pharmala Biotech Holdings Inc. | 58.49 Thousand CAD | -6464.664% |
| Doseology Sciences Inc. | -1.06 Million CAD | 462.188% |
| MYND Life Sciences Inc. | 2.99 Million CAD | -28.011% |
| Nova Mentis Life Science Corp. | -8088.00 CAD | 47577.745% |
| PharmaTher Holdings Ltd. | -2.13 Million CAD | 280.009% |
| PreveCeutical Medical Inc. | 3.83 Million CAD | -0.189% |
| Telescope Innovations Corp. | -719.49 Thousand CAD | 633.709% |